HMDB0000068 | Epinephrine | 51-43-4 |  | C9H13NO3 | 183.2044 183.089543287 | Not Available |
HMDB0000819 | Normetanephrine | 97-31-4 |  | C9H13NO3 | 183.2044 183.089543287 | Not Available |
HMDB0004061 | 3-Methoxy-4-hydroxyphenylglycolaldehyde | 17592-23-3 |  | C9H10O4 | 182.1733 182.057908808 | Not Available |
HMDB0004076 | 5-Hydroxykynurenamine | 708-23-6 |  | C9H12N2O2 | 180.2038 180.089877638 | Not Available |
HMDB0060281 | 3-Hydroxykynurenamine | |  | C9H12N2O2 | 180.2038 180.089877638 | Not Available |
HMDB0000259 | Serotonin | 50-67-9 |  | C10H12N2O | 176.2151 176.094963016 | Not Available |
HMDB0004073 | 5-Hydroxyindoleacetaldehyde | 1892-21-3 |  | C10H9NO2 | 175.184 175.063328537 | Not Available |
HMDB0000216 | Norepinephrine | 51-41-2 |  | C8H11NO3 | 169.1778 169.073893223 | Not Available |
HMDB0006242 | 3,4-Dihydroxymandelaldehyde | 13023-73-9 |  | C8H8O4 | 168.1467 168.042258744 | Not Available |
HMDB0000022 | 3-Methoxytyramine | 554-52-9 |  | C9H13NO2 | 167.205 167.094628665 | Not Available |
HMDB0002182 | Phenylephrine | 59-42-7 |  | C9H13NO2 | 167.205 167.094628665 | Not Available |
HMDB0005175 | Homovanillin | 5703-24-2 |  | C9H10O3 | 166.1739 166.062994186 | Not Available |
HMDB0001943 | Pseudoephedrine | 90-82-4 |  | C10H15NO | 165.2322 165.115364107 | Not Available |
HMDB0001934 | Nicotine | 54-11-5 |  | C10H14N2 | 162.2316 162.115698458 | - Lewis AJ, Truman P, Hosking MR, Miller JH: Monoamine oxidase inhibitory activity in tobacco smoke varies with tobacco type. Tob Control. 2012 Jan;21(1):39-43. doi: 10.1136/tc.2010.040287. Epub 2011 Jun 2. [PubMed:21636610 ]
- Leroy C, Bragulat V, Berlin I, Gregoire MC, Bottlaender M, Roumenov D, Dolle F, Bourgeois S, Penttila J, Artiges E, Martinot JL, Trichard C: Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone. J Clin Psychopharmacol. 2009 Feb;29(1):86-8. doi: 10.1097/JCP.0b013e31819e98f. [PubMed:19142115 ]
|
HMDB0004077 | 4,6-Dihydroxyquinoline | 3517-61-1 |  | C9H7NO2 | 161.1574 161.047678473 | Not Available |
HMDB0060289 | Quinoline-4,8-diol | |  | C9H7NO2 | 161.1574 161.047678473 | Not Available |
HMDB0000303 | Tryptamine | 61-54-1 |  | C10H12N2 | 160.2157 160.100048394 | Not Available |
HMDB0015563 | Pargyline | 555-57-7 |  | C11H13N | 159.2276 159.104799421 | - Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
- Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841 ]
- Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422 ]
- Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646 ]
- Murphy DL, Karoum F, Pickar D, Cohen RM, Lipper S, Mellow AM, Tariot PN, Sunderland T: Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J Neural Transm Suppl. 1998;52:39-48. [PubMed:9564606 ]
- Fuentes JA, Ordaz A, Neff NH: Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7. [PubMed:477738 ]
|
HMDB0001190 | Indoleacetaldehyde | 2591-98-2 |  | C10H9NO | 159.1846 159.068413915 | Not Available |
HMDB0000073 | Dopamine | 62-31-7 |  | C8H11NO2 | 153.1784 153.078978601 | - Bortolato M, Chen K, Shih JC: Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1527-33. doi: 10.1016/j.addr.2008.06.002. Epub 2008 Jul 4. [PubMed:18652859 ]
- Kaludercic N, Carpi A, Menabo R, Di Lisa F, Paolocci N: Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32. doi: 10.1016/j.bbamcr.2010.09.010. Epub 2010 Sep 24. [PubMed:20869994 ]
- Volavka J, Bilder R, Nolan K: Catecholamines and aggression: the role of COMT and MAO polymorphisms. Ann N Y Acad Sci. 2004 Dec;1036:393-8. [PubMed:15817751 ]
|
HMDB0003791 | 3,4-Dihydroxyphenylacetaldehyde | 5707-55-1 |  | C8H8O3 | 152.1473 152.047344122 | Not Available |
HMDB0001942 | Phenylpropanolamine | 14838-15-4 |  | C9H13NO | 151.2056 151.099714043 | Not Available |
HMDB0014337 | Phentermine | 122-09-8 |  | C10H15N | 149.2328 149.120449485 | - Rothman RB: Is phentermine an inhibitor of monoamine oxidase? A critical appraisal. Synapse. 1999 May;32(2):141-5. [PubMed:10231134 ]
- Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660 ]
- Kilpatrick IC, Traut M, Heal DJ: Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1454-8. [PubMed:11673765 ]
- Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838 ]
|
HMDB0015517 | Methamphetamine | 537-46-2 |  | C10H15N | 149.2328 149.120449485 | - Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613 ]
- Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660 ]
|
HMDB0000306 | Tyramine | 51-67-2 |  | C8H11NO | 137.179 137.084063979 | Not Available |